Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SAMD4A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SAMD4A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SAMD4A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SAMD4A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190331110 | Endometrium | AEH | regulation of mRNA metabolic process | 77/2100 | 288/18723 | 1.69e-13 | 4.40e-11 | 77 |
GO:000989616 | Endometrium | AEH | positive regulation of catabolic process | 104/2100 | 492/18723 | 9.38e-11 | 1.10e-08 | 104 |
GO:003133116 | Endometrium | AEH | positive regulation of cellular catabolic process | 91/2100 | 427/18723 | 9.15e-10 | 8.31e-08 | 91 |
GO:000640210 | Endometrium | AEH | mRNA catabolic process | 59/2100 | 232/18723 | 9.51e-10 | 8.52e-08 | 59 |
GO:000641716 | Endometrium | AEH | regulation of translation | 94/2100 | 468/18723 | 1.14e-08 | 7.62e-07 | 94 |
GO:000640110 | Endometrium | AEH | RNA catabolic process | 63/2100 | 278/18723 | 3.28e-08 | 1.87e-06 | 63 |
GO:004572715 | Endometrium | AEH | positive regulation of translation | 38/2100 | 136/18723 | 6.37e-08 | 3.38e-06 | 38 |
GO:003425015 | Endometrium | AEH | positive regulation of cellular amide metabolic process | 42/2100 | 162/18723 | 1.35e-07 | 6.12e-06 | 42 |
GO:006101310 | Endometrium | AEH | regulation of mRNA catabolic process | 39/2100 | 166/18723 | 5.21e-06 | 1.33e-04 | 39 |
GO:004348810 | Endometrium | AEH | regulation of mRNA stability | 37/2100 | 158/18723 | 9.73e-06 | 2.24e-04 | 37 |
GO:19033137 | Endometrium | AEH | positive regulation of mRNA metabolic process | 30/2100 | 118/18723 | 1.21e-05 | 2.68e-04 | 30 |
GO:003465510 | Endometrium | AEH | nucleobase-containing compound catabolic process | 74/2100 | 407/18723 | 1.78e-05 | 3.65e-04 | 74 |
GO:004427010 | Endometrium | AEH | cellular nitrogen compound catabolic process | 80/2100 | 451/18723 | 2.09e-05 | 4.13e-04 | 80 |
GO:00467009 | Endometrium | AEH | heterocycle catabolic process | 79/2100 | 445/18723 | 2.27e-05 | 4.35e-04 | 79 |
GO:004348710 | Endometrium | AEH | regulation of RNA stability | 38/2100 | 170/18723 | 2.30e-05 | 4.38e-04 | 38 |
GO:00194399 | Endometrium | AEH | aromatic compound catabolic process | 80/2100 | 467/18723 | 7.21e-05 | 1.10e-03 | 80 |
GO:19013619 | Endometrium | AEH | organic cyclic compound catabolic process | 83/2100 | 495/18723 | 1.13e-04 | 1.60e-03 | 83 |
GO:00009568 | Endometrium | AEH | nuclear-transcribed mRNA catabolic process | 26/2100 | 112/18723 | 2.25e-04 | 2.75e-03 | 26 |
GO:00002897 | Endometrium | AEH | nuclear-transcribed mRNA poly(A) tail shortening | 10/2100 | 29/18723 | 8.25e-04 | 7.72e-03 | 10 |
GO:00610147 | Endometrium | AEH | positive regulation of mRNA catabolic process | 20/2100 | 87/18723 | 1.30e-03 | 1.11e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SAMD4A | SNV | Missense_Mutation | | c.361G>A | p.Glu121Lys | p.E121K | Q9UPU9 | protein_coding | tolerated(0.05) | probably_damaging(0.918) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SAMD4A | SNV | Missense_Mutation | | c.570N>T | p.Trp190Cys | p.W190C | Q9UPU9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AR-A24N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SAMD4A | SNV | Missense_Mutation | | c.1589N>C | p.Ile530Thr | p.I530T | Q9UPU9 | protein_coding | tolerated(0.63) | benign(0.001) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
SAMD4A | SNV | Missense_Mutation | | c.820N>A | p.Glu274Lys | p.E274K | Q9UPU9 | protein_coding | deleterious(0.04) | benign(0.321) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
SAMD4A | deletion | Frame_Shift_Del | | c.866delN | p.Leu291CysfsTer7 | p.L291Cfs*7 | Q9UPU9 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SAMD4A | insertion | Frame_Shift_Ins | novel | c.523dupC | p.His175ProfsTer10 | p.H175Pfs*10 | Q9UPU9 | protein_coding | | | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
SAMD4A | insertion | Nonsense_Mutation | novel | c.524_525insAGGATAAAGTGATTTCCCTCCTGTTAACTCATCTGCCTTTG | p.His175GlnfsTer3 | p.H175Qfs*3 | Q9UPU9 | protein_coding | | | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
SAMD4A | deletion | Frame_Shift_Del | | c.866delN | p.Leu291CysfsTer7 | p.L291Cfs*7 | Q9UPU9 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
SAMD4A | SNV | Missense_Mutation | | c.931N>G | p.Gln311Glu | p.Q311E | Q9UPU9 | protein_coding | tolerated(0.2) | benign(0.015) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SAMD4A | SNV | Missense_Mutation | | c.1540N>A | p.Asp514Asn | p.D514N | Q9UPU9 | protein_coding | deleterious(0) | benign(0.146) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |